<DOC>
	<DOCNO>NCT00008554</DOCNO>
	<brief_summary>The purpose study compare GW433908 nelfinavir give abacavir lamivudine HIV patient take antiretroviral drug .</brief_summary>
	<brief_title>Comparison GW433908 Nelfinavir HIV Patients Who Have Not Had Antiretroviral Therapy</brief_title>
	<detailed_description>Patients randomize 2:1 scheme 1 2 treatment group . Group 1 receive GW433908 plus abacavir ( ABC ) plus lamivudine ( 3TC ) ; Group 2 receives nelfinavir ( NFV ) plus ABC plus 3TC . Patients undergo safety efficacy assessment Screening Visit , Day 1 ( Entry ) , Weeks 1 , 2 , 4 , 8 , 12 , 16 , 20 , 24 , every 8 week thereafter . A follow-up visit perform 4 week permanent discontinuation study drug . Detailed assessment development lipodystrophy/fat redistribution occur Day 1 , Week 24 , Week 48 , every 16 week thereafter . Patients examination laboratory test perform visit .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are least 13 year old ( consent parent guardian require 18 ) . Agree use proven barrier method birth control ( e.g. , spermicide plus condom ) study period ( hormonal birth control accept ) , able child . Have receive less 4 week treatment nucleoside reverse transcriptase inhibitor ( NRTI ) never receive nonnucleoside reverse transcriptase inhibitor ( NNRT ) protease inhibitor ( PI ) . Have viral load ( amount HIV blood ) 5,000 copies/ml , positive result screen visit . Exclusion Criteria Patients eligible study : Abuse drug alcohol way would interfere study , opinion doctor . Patients stable methadone consider participation . Have active/acute CDC Category C event . Are unable absorb take medicine mouth . Are pregnant breastfeeding . Have serious medical condition ( diabetes , heart problem , hepatitis ) might affect safety patient . Have pancreatitis hepatitis within last 6 month . Have treat radiation chemotherapy within 28 day study drug take , need study . Have take drug affect immune system ( corticosteroid , interleukin , interferon ) antiHIV activity ( hydroxyurea foscarnet ) within 28 day study drug take . Have receive HIV vaccine within 3 month study drug take . Have receive certain drug within 28 day study drug take , think need study . Have receive experimental treatment . Have allergy might interfere study , opinion doctor .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2001</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>abacavir</keyword>
</DOC>